Brett Monia Sells 21,072 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

by · The Markets Daily

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) CEO Brett Monia sold 21,072 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $78.49, for a total value of $1,653,941.28. Following the sale, the chief executive officer owned 245,571 shares in the company, valued at approximately $19,274,867.79. The trade was a 7.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Stock Up 3.6%

NASDAQ IONS traded up $2.84 on Friday, reaching $81.18. The company had a trading volume of 3,828,233 shares, compared to its average volume of 1,762,614. The firm has a market capitalization of $13.42 billion, a PE ratio of -39.22 and a beta of 0.37. Ionis Pharmaceuticals, Inc. has a 1 year low of $39.37 and a 1 year high of $86.74. The firm has a 50-day moving average of $75.03 and a 200-day moving average of $77.36. The company has a debt-to-equity ratio of 2.75, a current ratio of 4.10 and a quick ratio of 4.09.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The company had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.56 million. During the same quarter last year, the firm posted ($0.93) earnings per share. The business’s quarterly revenue was up 86.4% on a year-over-year basis. On average, equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. Stifel Nicolaus lifted their target price on Ionis Pharmaceuticals from $73.00 to $77.00 and gave the stock a “hold” rating in a research report on Thursday, February 26th. Royal Bank Of Canada increased their price target on Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, April 30th. Raymond James Financial began coverage on Ionis Pharmaceuticals in a research note on Friday, April 10th. They set an “outperform” rating and a $104.00 price objective for the company. Finally, Canaccord Genuity Group assumed coverage on Ionis Pharmaceuticals in a research report on Monday, April 20th. They issued a “buy” rating and a $110.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $102.90.

Check Out Our Latest Analysis on Ionis Pharmaceuticals

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Brown Brothers Harriman & Co. acquired a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth $27,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Ionis Pharmaceuticals in the 1st quarter worth about $30,000. Quarry LP acquired a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at about $38,000. Hilton Head Capital Partners LLC bought a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at about $47,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at about $47,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Key Stories Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

  • Positive Sentiment: Ionis received FDA approval expanding TRYNGOLZA to treat severe hypertriglyceridemia, strengthening the drug’s commercial opportunity and making it the first approved therapy for the condition. Article Title
  • Positive Sentiment: Ionis announced a licensing deal with Recordati for ex-U.S. rights to zilganersen in Alexander disease, which provides upfront and royalty potential while allowing Ionis to keep U.S. commercialization rights. Article Title
  • Positive Sentiment: Leerink Partners raised its price target on Ionis, signaling continued analyst confidence in the company’s pipeline and commercial execution. Article Title
  • Neutral Sentiment: HC Wainwright kept a Buy rating but lowered some 2027 EPS estimates, which is a mild headwind but not a major shift in the firm’s overall view. Article Title

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

Featured Stories